MAGE-A3

BIOLOGICAL2 trials

Sponsors

University of Arkansas, University of Maryland, Baltimore

Conditions

Multiple MyelomaSquamous Cell Carcinoma of the Head and Neck

Phase 1

0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck

CompletedNCT00257738

University of Maryland, BaltimoreSquamous Cell Carcinoma of the Head and Neck

Start: 2005-11-30End: 2012-10-31Updated: 2019-10-17

Phase 2

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

CompletedNCT00090493

University of ArkansasMultiple Myeloma

Start: 2004-06-30End: 2012-05-31Updated: 2013-06-24

Related Papers

A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology2014-05-204 citations